4.6 Article

BT2 Suppresses Human Monocytic-Endothelial Cell Adhesion, Bone Erosion and Inflammation

Journal

JOURNAL OF INFLAMMATION RESEARCH
Volume 14, Issue -, Pages 1019-1028

Publisher

DOVE MEDICAL PRESS LTD
DOI: 10.2147/JIR.S296676

Keywords

inflammation; pathology; bone erosion; rheumatoid arthritis; dibenzoxazepinone

Categories

Funding

  1. National Health and Medical Research Council of Australia (NHMRC)
  2. Cancer Institute New South Wales (CINSW)
  3. National Heart Foundation of Australia

Ask authors/readers for more resources

BT2 is a novel small molecule inhibitor that effectively suppresses joint inflammation, bone erosion, pro-inflammatory cytokines, and adhesion molecule expression, showing potential clinical utility as a new anti-inflammatory agent.
Introduction: Inflammation and bone erosion are processes key to the pathogenesis of rheumatoid arthritis, a systemic autoimmune disease causing progressive disability and pain, impacting around 1.3 million people in the United States alone. However, many patients do not respond sufficiently to existing therapies or benefit is not sustained and alternate therapeutic approaches are lacking. We recently identified the dibenzoxazepinone BT2, which inhibits ERK phosphorylation, from a high-throughput chemical screen and identified its ability to inhibit angiogenesis and vascular leakiness. Methods: Here we evaluated BT2 for potential anti-inflammatory activity in in vitro models of human monocytic-endothelial cell adhesion, monocytic cell extravasation and collagen antibody-induced arthritis in mice. Results: BT2 inhibits human monocytic cell adhesion to IL-1 beta-treated human endothelial cells and inhibits monocytic transendothelial migration toward MCP-1. In mice rendered arthritic, single systemic administration of BT2 prevented footpad swelling, bone destruction and TRAP(+) cells in the joints. BT2 suppressed inducible circulating levels of IL-1 beta, IL-2 and IL-6 to normal levels without affecting levels of IL-4 or IL-10 among other cytokines. BT2 also inhibited the expression of pro-inflammatory adhesion molecules ICAM-1 and VCAM-1 in arthritic joints. There was no evidence of toxicity following intraperitoneal, gavage or intraarticular administration of BT2. Conclusion: BT2 is a novel small molecule inhibitor of joint inflammation, bone erosion, pro-inflammatory cytokine and adhesion molecule expression. This suggests the potential clinical utility of BT2 as a new anti-inflammatory agent.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available